Related references
Note: Only part of the references are listed.Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Neuroprotective potential of high-dose biotin
Mark F. McCarty et al.
MEDICAL HYPOTHESES (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High dose biotin as treatment for progressive multiple sclerosis
Gary Birnbaum et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis
Christine Lebrun et al.
NEUROLOGY AND THERAPY (2017)
High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference
Marie-Liesse Piketty et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
Laure Peyro Saint Paul et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
High doses of biotin in chronic progressive multiple sclerosis: A pilot study
Frederic Sedel et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Natural, innate improvements in multiple sclerosis disability
Helen Tremlett et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Bruce D. Trapp et al.
LANCET NEUROLOGY (2009)
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
O Andersen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Cladribine and progressive MS - Clinical and MRI outcomes of a multicenter controlled trial
GPA Rice et al.
NEUROLOGY (2000)
Share Paper
